Professor Bin Yu obtained his PhD degree from Zhengzhou University and University of Cambridge and currently is a professor of medicinal chemistry at School of Pharmaceutical Sciences, Zhengzhou University. His research interests focus on chemistry driven drug discovery for novel therapeutics. To date, he has published over 120 papers in international high-impact peer-reviewed journals including Journal of Medicinal Chemistry, Organic Letters, Pharmacology & Therapeutics, Journal of Hematology & Oncology, Drug Discovery Today, Acta Pharmaceutica Sinica B, etc., 10 of them were published in journal with impact factor (IF) >10.

• 1. Evolution of drug discovery and the impact of technological innovations2. AI in drug discovery for novel therapeutics3. Landiolol: pharmacology and its use for rate control in atrial fibrillation in an emergency setting4. Deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata5. Berdazimer sodium (Zelsuvmi), a medication used for the treatment for molluscum contagiosum6. Cefepime/Enmetazobactam: a microbiological, pharmacokinetic, pharmacodynamic, and clinical evaluation7. Aprocitentan, a Newly Approved Drug for Resistant Hypertension8. Givinostat (Duvyzat), a potential treatment for Duchenne muscular dystrophy9. Vadadustat, an orally administered inhibitor of HIF-PH with a safety and efficacy profile for the treatment of anemia in patients with CKD10. Danicopan: an oral complement factor D inhibitor for paroxysmal nocturnal hemoglobinuria11. Tovorafenib, an oral, brain-penetrant, highly-selective type II RAF kinase inhibitor12. Lazertinib, a tyrosine kinase inhibitor used in combination with amivantamab to treat non-small cell lung cancer with EGFR mutations13. Journavx (suzetrigine), a First-in-Class Treatment for Adults With Moderate-to-Severe Acute Pain14. Symbravo (meloxicam and rizatriptan), a non-steroidal anti-inflammatory drug for the Acute Treatment of Migraine with or without Aura in Adults15. Grafapex (treosulfan), an alkylating agent for Allogeneic Hematopoietic Stem Cell Transplantation16. Alyftrek, a next-in-class, triple combination cystic fibrosis transmembrane conductance regulator (CFTR) modulator for the treatment of cystic fibrosis17. Tryngolza (olezarsen), an apoC-III-directed antisense oligonucleotide to reduce triglycerides in adults with familial chylomicronemia syndrome18. Prospective analysis of approved drugs

Professor Bin Yu obtained his PhD degree from Zhengzhou University and University of Cambridge and currently is a professor of medicinal chemistry at School of Pharmaceutical Sciences, Zhengzhou University. His research interests focus on chemistry driven drug discovery for novel therapeutics. To date, he has published over 120 papers in international high-impact peer-reviewed journals including Journal of Medicinal Chemistry, Organic Letters, Pharmacology & Therapeutics, Journal of Hematology & Oncology, Drug Discovery Today, Acta Pharmaceutica Sinica B, etc., 10 of them were published in journal with impact factor (IF) >10.

• 1. Evolution of drug discovery and the impact of technological innovations2. AI in drug discovery for novel therapeutics3. Landiolol: pharmacology and its use for rate control in atrial fibrillation in an emergency setting4. Deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata5. Berdazimer sodium (Zelsuvmi), a medication used for the treatment for molluscum contagiosum6. Cefepime/Enmetazobactam: a microbiological, pharmacokinetic, pharmacodynamic, and clinical evaluation7. Aprocitentan, a Newly Approved Drug for Resistant Hypertension8. Givinostat (Duvyzat), a potential treatment for Duchenne muscular dystrophy9. Vadadustat, an orally administered inhibitor of HIF-PH with a safety and efficacy profile for the treatment of anemia in patients with CKD10. Danicopan: an oral complement factor D inhibitor for paroxysmal nocturnal hemoglobinuria11. Tovorafenib, an oral, brain-penetrant, highly-selective type II RAF kinase inhibitor12. Lazertinib, a tyrosine kinase inhibitor used in combination with amivantamab to treat non-small cell lung cancer with EGFR mutations13. Journavx (suzetrigine), a First-in-Class Treatment for Adults With Moderate-to-Severe Acute Pain14. Symbravo (meloxicam and rizatriptan), a non-steroidal anti-inflammatory drug for the Acute Treatment of Migraine with or without Aura in Adults15. Grafapex (treosulfan), an alkylating agent for Allogeneic Hematopoietic Stem Cell Transplantation16. Alyftrek, a next-in-class, triple combination cystic fibrosis transmembrane conductance regulator (CFTR) modulator for the treatment of cystic fibrosis17. Tryngolza (olezarsen), an apoC-III-directed antisense oligonucleotide to reduce triglycerides in adults with familial chylomicronemia syndrome18. Prospective analysis of approved drugs

Professor Bin Yu obtained his PhD degree from Zhengzhou University and University of Cambridge and currently is a professor of medicinal chemistry at School of Pharmaceutical Sciences, Zhengzhou University. His research interests focus on chemistry driven drug discovery for novel therapeutics. To date, he has published over 120 papers in international high-impact peer-reviewed journals including Journal of Medicinal Chemistry, Organic Letters, Pharmacology & Therapeutics, Journal of Hematology & Oncology, Drug Discovery Today, Acta Pharmaceutica Sinica B, etc., 10 of them were published in journal with impact factor (IF) >10.

• 1. Evolution of drug discovery and the impact of technological innovations2. AI in drug discovery for novel therapeutics3. Landiolol: pharmacology and its use for rate control in atrial fibrillation in an emergency setting4. Deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata5. Berdazimer sodium (Zelsuvmi), a medication used for the treatment for molluscum contagiosum6. Cefepime/Enmetazobactam: a microbiological, pharmacokinetic, pharmacodynamic, and clinical evaluation7. Aprocitentan, a Newly Approved Drug for Resistant Hypertension8. Givinostat (Duvyzat), a potential treatment for Duchenne muscular dystrophy9. Vadadustat, an orally administered inhibitor of HIF-PH with a safety and efficacy profile for the treatment of anemia in patients with CKD10. Danicopan: an oral complement factor D inhibitor for paroxysmal nocturnal hemoglobinuria11. Tovorafenib, an oral, brain-penetrant, highly-selective type II RAF kinase inhibitor12. Lazertinib, a tyrosine kinase inhibitor used in combination with amivantamab to treat non-small cell lung cancer with EGFR mutations13. Journavx (suzetrigine), a First-in-Class Treatment for Adults With Moderate-to-Severe Acute Pain14. Symbravo (meloxicam and rizatriptan), a non-steroidal anti-inflammatory drug for the Acute Treatment of Migraine with or without Aura in Adults15. Grafapex (treosulfan), an alkylating agent for Allogeneic Hematopoietic Stem Cell Transplantation16. Alyftrek, a next-in-class, triple combination cystic fibrosis transmembrane conductance regulator (CFTR) modulator for the treatment of cystic fibrosis17. Tryngolza (olezarsen), an apoC-III-directed antisense oligonucleotide to reduce triglycerides in adults with familial chylomicronemia syndrome18. Prospective analysis of approved drugs